CTX310 vs NNC0491-6075

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atherosclerotic Cardiovascular Disease

Shared mechanism: ANGPTL3 · full Atherosclerotic Cardiovascular Disease pipeline

CTX310

Developed by CRISPR Therapeutics

Phase 1 in Atherosclerotic Cardiovascular Diseasegene editing (CRISPR-Cas9)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: June 2027 · NCT07491172 (registry estimate)

No aligned efficacy figure on record for this race.

NNC0491-6075

Developed by Novo Nordisk

Phase 1 in Atherosclerotic Cardiovascular Diseasemonoclonal antibody
Weak signal

NCT05979428 · Phase 1 · completed

Participants were randomly assigned to drug or placebo under quadruple-blind conditions across ascending-dose cohorts, a sound early-safety design, but the primary measure was the number of adverse events rather than a clinical or lipid outcome, and results have not yet been reported. Its registered primary outcome on ClinicalTrials.gov is "Part A (SAD): Number of treatment emergent adverse events (TEAEs)" (with 2 other safety or dose-finding measures). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

No aligned efficacy figure on record for this race.

Results for Atherosclerotic Cardiovascular Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCTX310NNC0491-6075
LDL-C, % change—Not reported—Not reported
Non-HDL-C, % change—Not reported—Not reported
ApoB, % change—Not reported—Not reported
Lp(a), % change—Not reported—Not reported
3-point MACE (% with event)—Not reported—Not reported

LDL-C, % change

CTX310
—Not reported
NNC0491-6075
—Not reported

Non-HDL-C, % change

CTX310
—Not reported
NNC0491-6075
—Not reported

ApoB, % change

CTX310
—Not reported
NNC0491-6075
—Not reported

Lp(a), % change

CTX310
—Not reported
NNC0491-6075
—Not reported

3-point MACE (% with event)

CTX310
—Not reported
NNC0491-6075
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

CTX310: no structured comparison results are available for Atherosclerotic Cardiovascular Disease.

NNC0491-6075: no structured comparison results are available for Atherosclerotic Cardiovascular Disease.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CTX310's landscape · NNC0491-6075's landscape